DNA damaging agents in combination with tyrosine kinase inhibitors

CAFC
  • US 7,838,512 B2
  • Filed: 05/02/2006
  • Issued: 11/23/2010
  • Est. Priority Date: 02/04/1994
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of improving chemotherapeutic intervention in a patient, the method comprising:

  • (a) administering a DNA damaging agent to the patient;

    (b) administering a therapeutically effective amount of a low molecular weight tyrosine kinase inhibitor to the patient, wherein the low molecular weight inhibitor binds intracellularly to inhibit the activity of more than one tyrosine kinase protein, and wherein the agent and the inhibitor act in combination by effecting a series of intracellular events to enhance cell death, thereby improving chemotherapeutic intervention.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×